OKUR
4:05 PM
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027 -- Hosted a Key Opinion Leader event highlighting the evolving PI3Kα treatment landscape and the
onkuretherapeutics.com